Sign In
Buy MYL
$15.86
+0 (+0%)
At Close: May 27, 2022
Blueprint Receives FDA Approval, And Other News: The Good, Bad And Ugly Of Biopharma
02:05am, Thursday, 10'th Sep 2020
FDA approves Blueprint’s GAVRETO for lung cancer. Regeneron reports positive data for Dupixent.
Change Healthcare Acquisition, And Other News: The Good, Bad And Ugly Of Biopharma
01:15pm, Friday, 21'st Aug 2020
Change Healthcare acquires medical imaging platform Nucleus.io. Mylan gets FDA nod for generic version of Tecfidera.
How to Trade Stocks That Hit All-Time Highs
06:26pm, Wednesday, 19'th Aug 2020
Apply this specialized set of risk management and technical rules when your positions are trading at new highs.
Los Angeles, California--(Newsfile Corp. - August 19, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mylan N.V. ("My
Mylan N.V. (NASDAQ: MYL) today announced the launch of the first FDA-approved therapeutically equivalent, substitutable generic of Biogen's Tecfidera® capsules. Dimethyl fumarate delayed release caps
Tracking John Paulson's Paulson & Company Portfolio - Q2 2020 Update
09:49am, Wednesday, 19'th Aug 2020
John Paulson’s 13F portfolio value increased from $2.62B to $3.13B this quarter. Paulson & Company's largest three positions are Bausch Health, Horizon Therapeutics, and SPDR Gold ETF.
Understanding Mylan's Unusual Options Activity
03:09pm, Tuesday, 18'th Aug 2020
Mylan (NASDAQ: MYL) shares experienced unusual options activity on Tuesday. The stock price moved down to $16.09 following the option alert. * Sentiment: BULLISH * Option Type: SWEEP * Trade Type:
Investors who take an interest in Mylan, Inc. (NASDAQ:MYL) should definitely note that the Vice Chairman & Lead...
Statement Pursuant to Section 19(a) of the Investment Company Act of 1940: DEX
08:39pm, Thursday, 13'th Aug 2020
On July 24, 2020, Delaware Enhanced Global Dividend and Income Fund (NYSE: DEX) (the "Fund"), a closed-end fund, paid a monthly distribution on its common stock of $0.0499 per share to shareholders of
Why Pfizer's 4% Yield Is Your Best Covid-19 Vaccine Play
12:24pm, Thursday, 13'th Aug 2020
I demonstrate why Pfizer is the best choice for dividend investors playing the Covid-19 vaccine theme.
Zydus Cadila launches India's cheapest remdesivir version at $37 per vial
04:14am, Thursday, 13'th Aug 2020
Zydus Cadila on Thursday launched the cheapest generic version of Gilead Sciences' antiviral drug remdesivir in India to treat COVID-19 following reports of shortages at hospitals in the world's third
ROSEN, A GLOBALLY RECOGNIZED FIRM, Reminds Mylan N.V. Investors of Important Deadline in Securities Class Action - MYL
07:38pm, Wednesday, 12'th Aug 2020
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7, 2019, inclusive (the "Class Period"), of the im
Mylan and Sesame Workshop Partner to Provide Socio-Emotional Support Resources to Families Impacted by COVID-19
01:00pm, Wednesday, 12'th Aug 2020
Mylan N.V. (NASDAQ: MYL) and Sesame Workshop, the non-profit educational organization behind Sesame Street, today announced a new effort to help children and families cope with the ongoing transitions
India's shortage of remdesivir is easing, says producer Cipla
02:28pm, Tuesday, 11'th Aug 2020
India's supply of antiviral drug remdesivir and generic equivalents is stabilising after shortages of the vital COVID-19 medicine at hospitals, according to a top executive at one of the country's big
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7, 2019, inclusive (the "Class Period"), of the im
